Measuring binding kinetics of ligands with tethered receptors by fluorescence polarization and total internal reflection fluorescence

Analytical Chemistry

Volumn 82, Issue 9, 2010, Pages 3819-3825

  Kwok, Ka Cheung ^a   Cheung, Nai Ho ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITIES; BINDING KINETICS; DIABETIC MICE; FLUORESCENCE POLARIZATION; GENISTEIN; GINSENOSIDES; HUMAN ESTROGEN RECEPTORS; NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; POLARIZATION ANISOTROPY; POTENTIAL LIGAND; TAMOXIFEN; THERAPEUTIC EFFECTS; TOTAL INTERNAL REFLECTION FLUORESCENCE;

AVIATION; BINDING ENERGY; CYTOLOGY; FLUORESCENCE; POLARIZATION; RATE CONSTANTS; REFRACTIVE INDEX; SURFACE PLASMON RESONANCE; TRANSCRIPTION FACTORS;

LIGANDS;

ESTROGEN RECEPTOR ALPHA; LIGAND;

ANIMAL; ARTICLE; CHEMISTRY; FLUORESCENCE; FLUORESCENCE POLARIZATION; HUMAN; KINETICS; METABOLISM; METHODOLOGY; MOUSE; PROTEIN BINDING;

ANIMALS; ESTROGEN RECEPTOR ALPHA; FLUORESCENCE; FLUORESCENCE POLARIZATION; HUMANS; KINETICS; LIGANDS; MICE; PROTEIN BINDING;

EID: 77951785292     PISSN: 00032700     EISSN: None     Source Type: Journal    
DOI: 10.1021/ac1002245     Document Type: Article

References (37)

1. Jordan, V. C. Cancer 1992, 70, 977-982
2. Current Status of Test Methods for Detecting Endocrine Disruptors: In Vitro Estrogen Receptor Binding Assays; NIH Publication 03-4504; National Institutes of Health, October 2002.
3. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery; Wiley Interscience: Hoboken, NJ, 2005.
4. Tummino, J. P. and Copeland, R. A. Biochemistry 2008, 47, 5481-5492
5. Protein-Ligand Interactions, Methods and Applications; Nienhaus, G. U., Ed.; Humana Press: Totowa, NJ, 2005.
6. Rich, R. L. and Myszka, D. G. Drug Discovery Today: Technol. 2004, 1, 301-308
7. Gavutis, M., Lata, S., Lamken, P., Muller, P., and Piehler, J. Biophys. J. 2005, 88, 4289-4302
8. Rich, R. L., Hoth, L. R., Geoghegan, K. F., Brown, T. A., LeMotte, P. K., Simons, S. P., Hensley, P., and Myszka, D. G. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 8562-8567
9. Hopkins, A. L., Groom, C. R., and Alex, A. Drug Discovery Today 2004, 9, 430-431
10. Lakowicz, J. R. Principles of Fluorescence Spectroscopy, 3rd ed.; Springer: New York, 2006.
11. Schmid, E. L., Tairi, A.-P., Hovius, R., and Vogel, H. Anal. Chem. 1998, 70, 1331-1338
12. Lieto, A. M., Cush, R. C., and Thompson, N. L. Biophys. J. 2003, 85, 3294-3302
13. Hsieh, H. V. and Thompson, N. L. Biochemistry 1995, 34, 12481-12488
14. Yeung, K. M., Lu, Z. J., and Cheung, N. H. Colloids Surf., B 2009, 69, 246-250
15. Kwok, K. C., Yeung, K. M., and Cheung, N. H. Langmuir 2007, 23, 1948-1952
16. Thoma, N. and Goody, R. S. In Kinetic Analysis of Macromolecules; Johnson, K. A., Ed.; Oxford University Press: Oxford, 2003; pp 153 - 170.
17. Motulsky, H. J. and Mahan, L. C. Mol. Pharmacol. 1984, 25, 1-9
18. Wilkinson, J. C., Stein, R. A., Guyer, C. A., Beechem, J. M., and Staros, J. V. Biochemistry 2001, 40, 10230-10242
19. Tairi, A.-P., Hovius, R., Pick, H., Blasey, H., Bernard, A., Suprenant, A., Lundström, K., and Vogel, H. Biochemistry 1998, 37, 15850-15864
20. We typically mixed 1 nM F with 20 μM of the competitor ligand. The competitor ligand was either E2 or DES. Their dissociation constants were 1.4 nM (see Table 1).
21. Myszka, D. G., He, X., Dembo, M., Morton, T. A., and Goldstein, B. Biophys. J. 1998, 75, 583-594
22. Kwok, K. C. Measuring Binding Kinetics of Ligands with Tethered Receptors by Fluorescence Polarization Complemented with Total Internal Reflection Fluorescence Microscopy. Ph.D. Thesis, Hong Kong Baptist University, 2010.
23. Kim, S. H., Tamrazi, A., Carlson, K. E., Daniels, J. R., Lee, I. Y., and Katzenellenbogen, J. A. J. Am. Chem. Soc. 2004, 126, 4754-4755
24. Wingren, C. and Borrebaeck, C. A. K. OMICS 2006, 10, 411-427
25. Ohno, K., Suzuki, S., Fukushima, T., Maeda, M., Santa, T., and Imai, K. Analyst 2003, 128, 1091-1096
26. Mueller, S. O., Simon, S., Chae, K., Metzler, M., and Korach, K. S. Toxicol. Sci. 2004, 80, 14-25
27. Clegg, N. J., Paruthiyil, S., Leitman, D. C., and Scanlan, T. S. J. Med. Chem. 2005, 48, 5989-6003
28. Grese, T. A. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14105-14110
29. Wijayaratne, A. L., Nagel, S. C., Paige, L. A., Christensen, D. J., Norris, J. D., Fowlkes, D. M., and McDonnell, D. P. Endocrinology 1999, 140, 5828-5840
30. Kuiper, G. G. J. M., Lemmen, J. G., Carlsson, B., Corton, J. C., Safe, S. H., van der Saag, P. T., van der Burg, B., and Gustafsson, J.-A. Endocrinology 1998, 139, 4252-4263
31. STAR Results: Raloxifene as Effective as Tamoxifen, Better Safety Profile. NCI Cancer Bulletin; National Cancer Institute, April 18, 2006; Vol. 3 (16).
32. Furukawa, T., Bai, C. X., Kaihara, A., Ozaki, E., Kawano, T., Nakay, Y., Awais, M., Sato, M., Umezawa, Y., and Kurokawa, J. Mol. Pharmacol. 2006, 70, 1916-1924
33. Shang, W., Yang, Y., Zhou, L., Jiang, B., Jin, H., and Chen, M. J. Endocrinol. 2008, 198, 561-569
34. Hwang, J. T., Lee, M. S., Kim, H. J., Sung, M. J., Kim, H. Y., Kim, M. S., and Kwon, D. Y. Phytother. Res. 2009, 23, 262-266
35. Huang, Y. Private communication.
36. Baker, M. E. and Chang, D. J. Biochem. Biophys. Res. Commun. 2009, 386, 516-520
37. Fluorescent ligands for AR, ERα, ERβ, GR, PPARα, PPARδ, PPARγ, PR, PXR (SXR), and VDR are available from Invitrogen.